Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 9
- Registration Number
- NCT03007992
- Locations
- 🇩🇪
Klinikum Frankfurt-Höchst Klinik für Gynäkologie und Geburtshilfe - Operative und konservative Gynäkologie, Gynäkologische Onkologie, Pränataldiagnostik, Geburtshilfe, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Düsseldorf, Frauenklinik, Dusseldorf, Germany
🇩🇪Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Gynäkologie, Halle, Germany
PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Shi Yanxia
- Target Recruit Count
- 320
- Registration Number
- NCT03006614
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 505
- Registration Number
- NCT02998528
- Locations
- 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Local Institution - 0151, Baltimore, Maryland, United States
🇺🇸Local Institution - 0006, Boston, Massachusetts, United States
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 144
- Registration Number
- NCT02991482
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Winterthur, Winterthur, Switzerland
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- University of Washington
- Registration Number
- NCT02985658
- Locations
- 🇺🇸
Seattle Cancer Care Allliance, Seattle, Washington, United States
MEtronomic TrEatment Option in Advanced bReast cAncer
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT02954055
- Locations
- 🇮🇹
Ospedale di Bolzano Oncologia Medica Via lorenz Bohler 5, Bolzano, Italy
🇮🇹"Antonio Perrino" Division of Medical Oncology Strada Statale 7 APPIA, Brindisi, Italy
🇮🇹IRST IRCCS Division of medical oncology Via Maroncelli 40, Meldola, Italy
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 178
- Registration Number
- NCT02915744
- Locations
- 🇺🇸
Investigator Site - Plantation, Plantation, Florida, United States
🇺🇸Investigator Site - Boston, Boston, Massachusetts, United States
🇺🇸Investigator Site - Columbus, Columbus, Ohio, United States
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 279
- Registration Number
- NCT02892123
- Locations
- 🇺🇸
Hoag Family Cancer Institute, Newport Beach, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Vinorelbine and Gemcitabine in Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 136
- Registration Number
- NCT02791373
- Locations
- 🇨🇭
Department for Medical Oncology; University Hospital/Inselspital, Berne, Switzerland
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02733380
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.